REG - Oxford Biomedica PLC - Acquisition of US viral vector facility

Oxford BioMedicaAnnouncement

Tue 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251007:nRSG3545Ca&default-theme=true

RNS Number : 3545C  Oxford Biomedica PLC  07 October 2025

 

 

 

OXB expands US footprint with acquisition of commercial-scale viral vector
facility in North Carolina

-       OXB acquires Resilience's site in North Carolina, an
FDA-approved, commercial-scale viral vector manufacturing facility

-       In line with OXB's previously announced strategy to add US GMP
capacity across drug substance and fill-finish to meet growing client demand

-       Strengthens OXB's global CDMO network and enhances service
offering for existing and prospective clients

-       Supports existing near and medium-term financial guidance

Oxford, UK - 7 October 2025: OXB (LSE: OXB), a global quality and
innovation-led cell and gene therapy CDMO, today announces that it has signed
and closed an asset purchase transaction to acquire a custom-built,
state-of-the-art cell and gene therapy viral vector manufacturing facility in
North Carolina from RTP Operating, LLC, a subsidiary of National Resilience
Holdco, Inc. (Resilience).

 

Commercial-scale GMP capacity in the US to meet demand from existing and new
clients

The acquisition expands OXB's viral vector manufacturing capabilities in the
US up to commercial-scale, increasing GMP capacity and enhancing services to
clients across North America. The FDA approved facility in Durham, North
Carolina adds scalable vector manufacturing capabilities and end-to-end
services across drug substance and fill-finish. This acquisition enables OXB
to support late-stage programmes and commercial launches from the US for new
and existing clients worldwide, particularly in the adeno-associated virus
(AAV) field. By leveraging an established, commercial-ready facility, the
acquisition will expedite OXB's ability to meet growing demand from existing
clients while supporting new business opportunities. Located in North
Carolina's biopharma hub at Research Triangle Park (RTP), the site brings a
skilled workforce and access to established industry networks.

 

Unified global network for multi-vector, multi-site manufacturing

The Durham, North Carolina site, complements OXB's global network across
Oxford, Lyon, Strasbourg and Bedford, MA, by adding US commercial-scale
capabilities. The site includes two operational GMP drug substance suites, a
dedicated fill-finish suite, a further GMP suite which is expansion-ready, as
well as on-site QC labs and warehousing. Following the acquisition, OXB's
Bedford, MA site will remain an AAV centre of excellence for process and
analytical development, focusing on early-stage development activities, with
the new site in North Carolina set to become a hub for clinical and commercial
activities.

 

This acquisition is in line with the Company's previously disclosed strategic
initiatives to expand its US commercial capabilities. In August 2025, the
Company raised c.£60 million gross proceeds through an equity placing in
order to support investment to strengthen its CDMO network, including
expansion of OXB's US commercial-scale GMP capacity and advance process
quality, productivity and yields.

 

Transaction details and expansion plans

Under the terms of the asset purchase agreement, OXB has paid $4.5 million
(£3.4 million) in consideration for the assets, funded by existing cash.
Integration planning has commenced, with key functions expected to be
operational by Q1 2026.  The Company expects to realise a single-digit gain
in 2025 as a result of the transaction which is anticipated to broadly offset
any acquisition-related and operational costs for the new site in 2025.

 

The Company intends to invest in the new facility in North Carolina including
hiring additional operational staff, in order to bring the site to full
commercial readiness, with increased US fill-finish capacity and faster client
onboarding. The Company will also continue to build on its previously
disclosed plans to make strategic investments in its existing sites to meet
growing client demand. Accordingly, its investment plans and capital
expenditure expectations remain largely consistent with those announced in
August 2025.

 

Transaction supports top-line growth; existing financial guidance unchanged

The Company's existing financial guidance remains unchanged, with the
acquisition supporting OXB's long-term top-line growth outlook and existing
near and medium-term financial guidance. The Company expects to deliver
above-market growth, achieve EBITDA profitability from FY 2025 (on a constant
currency basis), and strengthen its competitive position in the global viral
vector market.

 

 

Dr. Frank Mathias, Chief Executive Officer of OXB, commented: "This
acquisition is a major milestone in OXB's evolution as a global,
innovation-led CDMO partner of choice. The FDA approved facility in North
Carolina adds commercial-scale US manufacturing capabilities, accelerating
OXB's ability to meet growing demand from existing clients while supporting
new business opportunities. It significantly expands our footprint in the
world's largest cell and gene therapy market and enhances our ability to
support clients globally across all major viral vector types and stages of
development, particularly those in the AAV field. By expanding our
capabilities in the US, we're executing on our growth strategy and unlocking
long-term value for both clients and shareholders."

 

 

-Ends-

 

Enquiries:

 

OXB:

T: +44 (0) 1865 509 737 / E: ir@oxb.com (mailto:ir@oxb.com)

Sophia Bolhassan, Head of Investor Relations

ICR Healthcare:

T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com

Mary-Jane Elliott / Angela Gray / Davide Salvi

 

 

About OXB

 

OXB (LSE: OXB) is a global quality and innovation-led contract development and
manufacturing organisation (CDMO) in cell and gene therapy with a mission to
enable its clients to deliver life changing therapies to patients around the
world.

 

One of the original pioneers in cell and gene therapy, OXB has 30 years of
experience in viral vectors; the driving force behind the majority of cell and
gene therapies. OXB collaborates with some of the world's most innovative
pharmaceutical and biotechnology companies, providing viral vector development
and manufacturing expertise in lentivirus, adeno-associated virus (AAV),
adenovirus and other viral vector types. OXB's world-class capabilities range
from early-stage development to commercialisation. These capabilities are
supported by robust quality-assurance systems, analytical methods and depth of
regulatory expertise.

 

OXB offers a vast number of technologies for viral vector manufacturing,
including a 4th generation lentiviral vector system (the TetraVecta™
system), a dual-plasmid system for AAV production, suspension and perfusion
process using process enhancers and stable producer and packaging cell lines.

 

OXB, a FTSE250 and FTSE4Good constituent, is headquartered in Oxford, UK. It
has development and manufacturing facilities across Oxfordshire, UK, Lyon and
Strasbourg, France, Bedford MA, and Durham NC, US. Learn more at www.oxb.com
(http://www.oxb.com) and follow us on LinkedIn
(https://www.linkedin.com/company/oxford-biomedica) and YouTube.
(https://www.youtube.com/oxfordbiomedica)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ACQEASEXELFSFEA